Introduction {#Sec1}
============

Treatment approaches in psoriasis range from traditional topical therapy and phototherapy to systemic interventions that target the immune system at different stages. Systemic therapies have advanced over time to target psoriasis-specific immune cytokines such as interleukin (IL)-12/23, or recently IL-17A, and their associated signaling pathways. Ustekinumab (an IL-12/23 inhibitor) has demonstrated good clinical efficacy in phase 3 studies with better Psoriasis Area Severity Index (PASI) response rates than those of etanercept (a tumor necrosis factor \[TNF\] inhibitor) \[[@CR1], [@CR2]\].

Secukinumab is a fully human monoclonal antibody that selectively neutralizes IL-17A, a key effector cytokine involved in the development of psoriasis \[[@CR3], [@CR4]\]. In the 52-week double-blinded CLEAR study, secukinumab (79.0%) was found to be superior to ustekinumab (57.6%) as assessed by PASI 90 response at Week 16 (*p* \< 0.0001) \[[@CR5]\] and Week 52 (*p* \< 0.0001) \[[@CR6]\]. Superior clinical efficacy with secukinumab was also associated with significantly greater improvement in health-related quality of life (HRQoL) when compared with ustekinumab. In the current study, we report 16-week results from the 52-week CLARITY study, the second head-to-head trial comparing secukinumab with ustekinumab in moderate to severe plaque psoriasis. Distinct from the CLEAR study, CLARITY includes a larger patient population (*N* = 1102 vs. *N* = 676), a greater proportion of US patients (64.2% vs. 12.6%), and an assessment of primary efficacy objectives at Week 12 (vs. Week 16).

Methods {#Sec2}
=======

Study Population {#Sec3}
----------------

Patients (≥ 18 years) with moderate to severe chronic plaque psoriasis (PASI ≥ 12, static 5-point Investigator's Global Assessment 2011 modified version \[IGA mod 2011\] score ≥ 3, and body surface area \[BSA\] involvement ≥ 10%) and who were inadequately controlled by topical treatments, phototherapy, and/or previous systemic therapy were eligible (key exclusion criteria are presented in Table S1).

Study Design {#Sec4}
------------

CLARITY (NCT02826603) is a multicenter, randomized, double-blinded, active-controlled, parallel-group, phase 3b trial. Eligible patients were randomized 1:1 to receive either subcutaneous secukinumab 300 mg at Baseline, Weeks 1, 2, and 3, and then every 4 weeks from Weeks 4 to 48, or subcutaneous ustekinumab (45 mg for patient weighing ≤ 100 kg or 90 mg for patient weighing \> 100 kg) at Baseline, Week 4, and then every 12 weeks (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Study design of the CLARITY study. ^¥^Ustekinumab dose is based on body weight at baseline; 45 mg for patient ≤ 100 kg; 90 mg for patient \> 100 kg. ^†^For patients with premature treatment discontinuation only. F4 = follow-up visit approximately 4 weeks after the EOT visit. F8 = follow-up visit approximately 8 weeks after the EOT visit. ↓ = active dose administration; in order to maintain blinding, patients received placebo administrations at several time points (not shown in this study design figure). The screening phase duration was at least 2 weeks and up to 4 weeks.*BL* baseline,*EOT* end of treatment phase

Study Objectives {#Sec5}
----------------

The co-primary objectives of the study were to demonstrate the superiority of secukinumab compared to ustekinumab with respect to PASI 90 response and IGA mod 2011 0/1 (clear or almost clear skin) at Week 12. The following key secondary objectives were assessed sequentially by a hierarchical testing strategy, which tested the superiority of secukinumab compared to ustekinumab with respect to (in hierarchical order): PASI 75 response at Week 12, PASI 75 response at Week 4, PASI 90 at Week 16, PASI 100 at Week 16, IGA mod 2011 0/1 at Week 16, PASI 100 at Week 12, and PASI 75 at Week 16. Dermatology Life Quality Index (DLQI) 0/1 response (representing no impact of skin disease on patients' quality of life) was also assessed at Weeks 4, 12, and 16.

Statistical Analyses {#Sec6}
--------------------

Co-primary variables and key secondary variables were evaluated using a logistic regression model with treatment group, baseline body weight strata (≤ 100 kg, \> 100 kg), and baseline PASI as explanatory variables. Missing values were handled by multiple imputation except for DLQI 0/1, where missing values were handled using last observation carried forward.

Study Oversight {#Sec7}
---------------

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.

Results {#Sec8}
=======

Study Population {#Sec9}
----------------

A total of 1102 patients, of whom almost two-thirds were US patients (64.2%), were randomized to either secukinumab 300 mg (*n* = 550) or ustekinumab 45/90 mg (*n* = 552). The rate of discontinuation was low and balanced between treatment arms (Fig. [2](#Fig2){ref-type="fig"}). Similarly, demographic and baseline disease characteristics were well balanced across patients (Table [1](#Tab1){ref-type="table"}).Fig. 2Patient disposition Table 1Patient demographic and baseline disease characteristicsCharacteristicsSecukinumab 300 mg (*n* = 550)Ustekinumab 45/90 mg (*n* = 552)Age, years (mean ± SD)45.4 ± 14.145.3 ± 14.2Gender--male, *n* (%)356 (64.7)376 (68.1)Race--Caucasian, *n* (%)414 (75.3)410 (74.3)Body weight (mean ± SD)\
\> 100 kg, *n* (%)91.0 ± 24.9\
189 (34.4)93.0 ± 24.9\
188 (34.1)PASI (mean ± SD)\
PASI \> 20, *n* (%)20.8 ± 9.0\
210 (38.2)21.3 ± 9.2\
226 (40.9)BSA affected,  % (mean ± SD)29.2 ± 17.929.5 ± 17.7IGA mod 2011---severe disease, *n* (%)209 (38.0)239 (43.3)Mean time since first diagnosis of plaque-type psoriasis, years (mean ± SD)16.8 ± 11.917.3 ± 13.3Previous exposure to biologic psoriasis therapy---yes, *n* (%)110 (20.0)130 (23.6)*BSA* body surface area, *IGA mod 2011* Investigator's Global Assessment 2011 modification, *PASI* Psoriasis Area and Severity Index, *SD* standard deviation

Efficacy {#Sec10}
--------

Both co-primary objectives were met: secukinumab was superior to ustekinumab for the proportion of patients that achieved PASI 90 responses at Week 12 (66.5% vs. 47.9%; *p* \< 0.0001) and for the proportion of patients that achieved IGA mod 2011 0/1 responses at Week 12 (72.3% vs. 55.4%; *p* \< 0.0001) (Fig. [3](#Fig3){ref-type="fig"}). Indeed, PASI 90 responses were greater with secukinumab compared to ustekinumab from as early as Week 4 (16.7% vs. 4.0%; *p* \< 0.0001),and out to Week 16 (76.6% vs. 54.2%; *p* \< 0.0001). Similarly, IGA mod 2011 0/1 findings were greater with secukinumab at Week 4 (26.9% vs. 7.8%; *p* \< 0.0001) and at Week 16 (78.6% vs. 59.1%; *p* \< 0.0001). Clear skin responses (PASI 100) were also greater among secukinumab treated patients compared to ustekinumab at every time point from Week 4 out to Week 16 (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3PASI 90 (**a**), IGA mod 2011 0/1 (**b**), and PASI 100 (**c**) responses out to Week 16. Missing values handled by multiple imputation.*IGA mod 2011 0/1* Investigator's Global Assessment, 2011 modification, clear (0) or almost clear (1) score,*PASI 90* Psoriasis Area and Severity Index 90% improvement vs. Baseline,*PASI 100* Psoriasis Area and Severity Index 100% improvement vs Baseline. \**p* \< 0.0001

All key secondary objectives assessing the superiority of secukinumab to ustekinumab were also met in the hierarchical testing strategy (Table [2](#Tab2){ref-type="table"}).Table 2Hierarchical efficacy analysis of key secondary objectives (% responders)ParametersSecukinumab 300 mg (*n* = 550)Ustekinumab 45/90 mg (*n* = 552)*p* valuePASI 75 at Week 1288.0%74.2%\< 0.0001PASI 75 at Week 440.2%16.3%\< 0.0001PASI 90 at Week 1676.6%54.2%\< 0.0001PASI 100 at Week 1645.3%26.7%\< 0.0001IGA mod 2011 0/1 at Week 1678.6%59.1%\< 0.0001PASI 100 at Week 1238.1%20.1%\< 0.0001PASI 75 at Week 1691.7%79.8%\< 0.0001*IGA mod 2011 0/1* investigator's global assessment 2011 modification clear (0) or almost clear (1), *PASI* psoriasis area and severity index

Quality of Life {#Sec11}
---------------

The proportion of patients with a DLQI 0/1 response was greater with secukinumab compared to ustekinumab at Week 4 (33.9% vs. 18.0%; *p* \< 0.0001), at Week 12 (64.0% vs. 51.7%; *p* \< 0.0001), and at Week 16 (68.4% vs. 55.9%; *p* \< 0.0001) (Fig. [4](#Fig4){ref-type="fig"}).Fig. 4DLQI 0/1 response out to Week 16. Missing values handled by last observation carried forward.*DLQI 0/1* Dermatology Life Quality Index 0/1 (representing no impact of skin disease on patients' quality of life). \**p *\< 0.0001

Safety {#Sec12}
------

Treatment-emergent adverse events (AEs) reported up to week 16 for both the secukinumab and ustekinumab treatment groups are presented in Table [3](#Tab3){ref-type="table"}. The total number of reported AEs was comparable between the secukinumab group (47.5%) and the ustekinumab group (46.4%). There were two deaths, one due to acute intoxication by cocaine and another due to sudden cardiac death (patient had a history of hypertension and atherosclerosis). The incidence of non-fatal serious AEs (SAEs) was low for both groups (2.5% for secukinumab and 1.6% for ustekinumab). AEs in the system organ class of "infections and infestations" were reported most often (22.2% for secukinumab and 21.2% for ustekinumab); however, most events were non-serious, manageable, and did not lead to study drug discontinuation. To maintain blinding until after the final database lock at Week 52, the distributions of rare AEs for both study treatments are not presented.Table 3Treatment-emergent adverse events to Week 16Treatment emergent AEsSecukinumab 300 mg (*n* = 550)Ustekinumab 45/90 mg (*n* = 552)Duration of exposure (subject years)170.8171.1All AEs261 (47.5)256 (46.4)All non-fatal SAEs14 (2.5)9 (1.6)Discontinued study treatment due to any AE11 (2.0)7 (1.3)Most frequent AEs^a^ Nasopharyngitis25 (4.5)25 (4.5) URTI25 (4.5)33 (6.0) Diarrhea17 (3.1)12 (2.2) Headache16 (2.9)15 (2.7) Sinusitis11 (2.0)7 (1.3)Infections and infestations122 (22.2)117 (21.2)Data are *n* (%) unless otherwise stated*AE* adverse event, *SAE* serious adverse event,*URTI*upper respiratory tract infection^a^By preferred term and occurring at an incidence of ≥ 2% in either treatment arm. AEs are listed in decreasing order of frequency in the secukinumab arm

Discussion {#Sec13}
==========

Psoriasis is a complex disease associated with a notable patient burden and comorbidity. Studies comparing the effectiveness of therapies in moderate to severe plaque psoriasis are important to facilitate an informed choice of treatment for patients. This 16-week analysis of the CLARITY study confirmed the superiority of secukinumab compared to ustekinumab in clearing skin, and achieving a greater quality of life improvement, in patients with moderate to severe plaque psoriasis.

Ustekinumab is a fully human monoclonal anti-IL-12/23 antibody, which has proved to be a safe and efficacious treatment for moderate to severe plaque psoriasis. PASI 90 response rates of approximately 42% were reported with ustekinumab (combined doses) in pivotal studies (PHOENIX 1, PHOENIX 2, and ACCEPT) after 12 weeks of treatment \[[@CR1], [@CR2], [@CR7]\]. Secukinumab is a fully human monoclonal anti-IL-17A antibody, which has shown long-lasting efficacy and safety for a variety of psoriasis manifestations, including psoriatic arthritis and psoriasis localized to the nails, scalp, palms, and soles \[[@CR5], [@CR8]--[@CR12]\]. In the double-blinded CLEAR study, secukinumab (79.0%) was found to be superior to ustekinumab (57.6%) in treating patients with moderate to severe plaque psoriasis, as assessed by PASI 90 response at Week 16 (*p* \< 0.0001) \[[@CR5]\]. In the present CLARITY study, it was again found that secukinumab had a superior PASI 90 response to ustekinumab, both at Week 12 (66.5% vs. 47.9%; *p* \< 0.0001) and at Week 16 (76.6% vs. 54.2%; *p* \< 0.0001). Secukinumab also demonstrated an earlier onset of response than ustekinumab; 40.2% of secukinumab-treated patients were PASI 75 responders as early as Week 4 compared to 16.3% (*p* \< 0.0001) of ustekinumab-treated patients.

In an era of more efficacious biologic treatments, a state of clear or almost clear skin is considered an achievable therapeutic target for psoriasis patients \[[@CR13], [@CR14]\]. In our study, a greater proportion of patients achieved clear or almost clear skin (IGA mod 2011 0/1) after 12 weeks of secukinumab treatment in comparison to ustekinumab treatment (72.3% vs. 55.4%; *p* \< 0.0001). Similarly, IGA mod 2011 0/1 rates were higher for those receiving secukinumab in comparison to ustekinumab at Week 16 (78.6% vs. 59.1%; *p* \< 0.0001). With secukinumab demonstrating superiority to ustekinumab for both PASI 90 and IGA mod 2011 0/1 responses at Week 12, both co-primary endpoints of the study were met.

Patients with psoriasis experience a significant impairment to their quality of life \[[@CR15]\]. Thus, it is recommended to include quality of life outcome measures as therapeutic targets \[[@CR13]\]. The proportion of patients reporting no impact of skin disease on their quality of life (DLQI 0/1 response) was examined in this study. We found that patients treated with secukinumab had superior improvements in DLQI 0/1 to ustekinumab at Weeks 12 (64.0% vs. 51.7%, respectively) and 16 (68.4% vs. 55.9%). These findings are similar to those reported in the CLEAR study, where the proportion of DLQI 0/1 responders was also greater at Week 16 with secukinumab (71.9%) compared to ustekinumab (57.4%) \[[@CR5]\].

Similar to previous secukinumab clinical trials, the safety profile of secukinumab remained favorable with no new safety signals identified to Week 16. Complete safety data from the 52-week CLARITY trial will be presented later.

This is the second head-to-head trial demonstrating the superior efficacy of secukinumab compared to ustekinumab in treating patients with moderate to severe psoriasis. The CLARITY study included a larger patient population (*N* = 1102 vs. *N* = 676) and a greater proportion of US patients (64.2% vs. 12.6%) than the CLEAR study.

A potential limitation of the CLARITY study is the absence of a placebo arm. Since both secukinumab and ustekinumab have previously demonstrated superior efficacy compared with placebo in phase 3 trials, the inclusion of a placebo arm here was considered unethical \[[@CR1], [@CR8]\]. In addition, while patient-reported DLQI was examined in the present study, other patient reported outcomes (such as relief of symptoms) were not. Previously, in the CLEAR study, secukinumab was found to be superior to ustekinumab at reducing psoriasis-related pain, itching, and scaling through 52 weeks of treatment \[[@CR6]\].

Conclusions {#Sec14}
===========

The results of this study confirm the superior efficacy of secukinumab over ustekinumab, with a rapid onset from Week 4, in treating patients with moderate to severe psoriasis.
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